2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.01 Conroy

PP01.01 Conroy - Poster

Pdf Summary

Plasma comprehensive genomic profiling (pCGP) is commonly used in non-small cell lung cancer (NSCLC) patients to detect actionable mutations and resistance mechanisms. This study analyzed data from 718 patients undergoing pCGP, focusing on EGFR-targeted therapy. Results showed divergent mutation profiles based on prior therapy lines, with pCGP impacting management in 28% of EGFR-mutated NSCLC cases, even prompting repeat testing in some instances. The study highlights the need for prospective research on the diagnostic and survival benefits of serial pCGP in this patient population. Notably, 18% of pre-treated patients with pCGP at progression exhibited resistance mutations treatable with FDA-approved therapy. Including ERBB2 and MET amplifications, 22% had actionable findings, with 58% successfully matched to targeted therapies based on pCGP results. By comparing plasma and tissue CGP, the study demonstrated the utility of pCGP in guiding treatment decisions when tissue biopsy was inconclusive. Overall, the findings underscore the clinical relevance of pCGP in identifying actionable mutations and guiding personalized therapy in EGFR-mutated NSCLC patients, emphasizing the potential for tailored treatment approaches based on genomic profiling data.

Keywords

Plasma comprehensive genomic profiling

pCGP

non-small cell lung cancer

NSCLC

actionable mutations

EGFR-targeted therapy

resistance mechanisms

prospective research

serial pCGP

FDA-approved therapy